The federal government told organizations receiving Strategic Science Fund dollars last month that it would pull back $20-million from the program. That decision came nearly two years after signing legally binding agreements with 17 research groups across the country.
Innovation, Science, and Economic Development Canada sent the news to recipients in late February. The cut affects organizations that signed contribution agreements back in May 2024. Those agreements locked in funding until 2028-29 and outlined exactly how money would flow and what results were expected.
Contribution agreements aren’t casual promises. They’re legal contracts that spell out dollar amounts, spending rules, and expected outcomes. Breaking them or changing terms mid-stream isn’t something departments typically do without serious cause.
Cate Murray runs the Stem Cell Network. She told reporters her organization will lose more than $1-million from the $48.48-million it was supposed to get over five years. She called the decision both surprising and disheartening.
“We did not believe that it was meant to flow through to recipients like us,” Murray said. “Our organizations are all on the front lines of working with biotechs, with developing next-generation talent, supporting patients, building science culture and education.”
Her network helps biotech researchers move regenerative medicine from lab benches to hospital bedsides. Clinical trials don’t come cheap, and cutting funding means fewer trials get done.
The email from ISED came from Andrea Smith, an assistant director general. She called it “disappointing news” but described the cut as relatively limited. The department framed it as a 2.26 per cent reduction across all funding years.
But that’s not how the math feels to recipients. The entire cut lands in 2028-29, the final funding year. That means organizations actually lose nine per cent of what they expected in that year.
Dr. Stéphanie Michaud runs BioCanRX, another group hit by the reduction. She confirmed that nine per cent figure. Her organization supports cancer researchers developing therapies and moving them into clinical trials. BioCanRX will lose roughly $860,000 from its initial $38-million award.
The email explicitly linked the cut to the comprehensive expenditure review. Finance Minister François-Philippe Champagne launched that review last summer. He directed cabinet colleagues to find savings that would climb to 15 per cent by 2028-29.
The goal was to trim day-to-day government operations while protecting investments that strengthen the economy. CBC News reported those details last July. The review comes as Prime Minister Mark Carney’s government focuses on defence spending and building economic independence from the United States amid President Donald Trump’s tariff threats.
Dr. Monique Dubé leads Braiding Knowledges Canada. Her organization funds Indigenous-led environmental research projects. She’ll lose $700,000 in 2028-29, which she called significant for an organization of her size.
Braiding Knowledges received $30.4-million total in 2024. The group funds community-led projects on natural resource development, climate change, and species sustainability. Dubé emphasized that all work happens within a reconciliation framework aligned with federal science priorities.
“Because we fund Indigenous communities and the work that they are leading, we need to do some significant planning with a cut of that magnitude,” Dubé said. She’s working with ISED to figure out how to reassign remaining funds without derailing community projects.
Industry Minister Mélanie Joly’s office was asked why the department would cut a program after signing binding agreements. ISED responded by email, saying some reductions were required as part of the comprehensive expenditure review. The department promised to minimize disruption to recipients.
The decision won’t affect the next call for applications planned for 2026-27, according to ISED. That competition would fund work between 2029-30 and 2033-34.
Gabrielle Landry, Joly’s spokesperson, told reporters the situation is “definitely not ideal” but stressed the government still invests in research and science. She pointed to $1.7-billion announced in December to attract international researchers. She also cited $900-million for the National Research Council tied to the new Defence Industrial Strategy and $20-million for 33 Genome Canada projects.
Genome Canada also faces cuts under this decision. A full list of impacted organizations includes 17 groups ranging from Actua to the Perimeter Institute for Theoretical Physics.
Michaud called the timing inconsistent. The government is talking about funding science while simultaneously cutting existing agreements. “We invest in biomanufacturing, we’re committed to made-in-Canada solutions, and so the kind of work that we do is very expensive,” she said.
She’ll now spend time hunting for other funding sources to cover the 2028-29 gap. Her team is small and already working flat out. Fundraising pulls focus from the actual research mission.
Murray said the Stem Cell Network will fund fewer clinical trials and cut back its Fueling Biotechnology program, which supports regenerative medicine startups. She estimates three to four fewer trials, which would typically help around 60 patients access new medicines.
She shared a success story from 2023. A world-first trial funded by her network treated pre-term infants at risk of chronic lung disease. The babies received stem cell transfusion therapy. Those infants are now hitting developmental milestones, Murray said. Their families returned to work. The kids went to preschool.
Both Murray and Michaud said they’ve never seen a department reopen contribution agreements this way. Agreements can be revisited if money is mismanaged or terms aren’t met. But unilateral cuts because of budget reviews? That’s new territory.
Murray doubts the program will be properly funded going forward. Michaud questions what message the government is sending. How can you cut existing agreements while promoting the next funding competition?
Dubé remains confident in her organization’s work. She views the cut as temporary but needs to manage it carefully to stay effective and position well for the next proposal round. She hopes the government will look beyond blanket percentage cuts and consider the actual value research organizations provide to the economy.
“I guess we have work to do with respect to communicating the value of this program,” Michaud said. She wants to sit down with government officials to determine a path forward and convey the importance of Strategic Science Fund activities.
Murray was more direct. She said the only fix is a political reversal.
The 17 impacted organizations span the research landscape. They include university-based networks, science education groups, and specialized research institutes. All signed agreements in good faith nearly two years ago. All are now adjusting plans for 2028-29.
The Strategic Science Fund was designed to support Canadian research infrastructure and talent development. It funds networks that bridge academic research and commercial application. The program helps position Canada as a competitive player in global science and innovation.
Cutting $20-million from an $800-million fund might sound modest on paper. But when that cut lands entirely in one year and hits organizations with tight budgets and long-term commitments, the impact multiplies. Clinical trials get delayed. Startup support shrinks. Community-led projects face uncertainty.
The comprehensive expenditure review was meant to find inefficiencies in government operations. Whether cutting research funding after signing legal agreements qualifies as finding inefficiency or creating new problems remains an open question. The affected organizations are left hoping for either a policy reversal or clarity about future funding priorities.
